Stock #14 Quarterly Update – Q4FY25 - English

Get the latest updates on our Pharma Stock's Q4 FY25 performance as we break down the key highlights from the quarter. While the company reported growth in its FY25 numbers, the results came in below market expectations, raising questions about the pace of its progress. We take a closer look at the company's strategic pivot—entering new segments and expanding into untapped markets—and how this transition phase is shaping the company’s future. However, the impact of these moves on Revenue and PAT may take time to materialize. Watch now to understand how they are navigating this evolving landscape, the challenges slowing near-term growth, and what its long-term roadmap could mean for investors.